CFCaterina Formichi

Caterina Formichi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Caterina Formichi has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Metabolomic profile differs between LADA and type 1 diabetes identifying tryptophan metabolism as a pathway involved in the heterogeneity of autoimmune diabetes

    by Ernesto Maddaloni, Samantha Pezzica, Rocco Amendolara, Silvia Sabatini, Gabriele Mocciaro, Guido Sebastiani, Luca D’ONofrio, Fabrizia Carli, Marta Tesi, Mara Suleiman, et al.

    Aims/hypothesis: The heterogeneity of autoimmune diabetes may be associated with variable metabolic alterations. Our aim was to investigate differences in the metabolomic and lipidomic profile of autoimmune diseases and to identify pathways linked to beta cell damage. To this end, we compared latent autoimmune diabetes in adults (LADA) and type 1 diabetes, also comparing them with rheumatoid arthritis (RA), a related autoimmune condition, and healthy control participants. Methods: Metabolomic and lipidomic analyses were performed for 136 individuals (49 with LADA, 44 with type 1 diabetes, 29 with RA and 14 control participants). Omics of pancreatic islets from healthy donors were also evaluated after in vitro treatment with proinflammatory cytokines. Results: LADA and type 1 diabetes differed from RA in terms of lipidomics and metabolomics. Phosphatidylethanolamines, ceramides, lysophosphatidylcholine and several metabolites at the entry sites of the tricarboxylic acid cycle were higher in type 1 diabetes compared with LADA. In pancreatic islets treated with proinflammatory cytokines, tryptophan concentration was reduced by 80%, indicating the activation of tryptophan metabolism in response to the inflammatory stimulus. In people with autoimmune disorders, kynurenine/tryptophan ratio (Kyn/Trp), a marker of tryptophan pathway activation, was higher than in the control group (Kyn/Trp ratio in control group, median [25th–75th percentile]: 0.014 [0.012–0.019]), with a progressive decline from RA (0.027 [0.022–0.032]) to LADA (0.021 [0.018–0.024]) and then to type 1 diabetes (0.018 [0.014–0.022]), ANCOVA p p =0.038). Conclusions/interpretation: Metabolomic and lipidomic profiles differ between LADA and type 1 diabetes and vs RA, providing new insights into the heterogeneity of autoimmune diabetes. Our results confirm the involvement of tryptophan metabolism in autoimmune disorders, suggesting that the impaired activation of this pathway of immune tolerance in LADA is less pronounced than in type 1 diabetes, consistent with its milder degree of beta cell loss.

  • Open Access

    Adherence to the mediterranean diet and risk of hypoglycemia in insulin-treated type 2 diabetic patients

    by Caterina Formichi, Sonia Caprio, Stefano Auddino, Felicia Rizza, Barbara Paolini, Laura Nigi, Francesco Dotta


  • Open Access

    Comprehensive sequencing profile and functional analysis of IsomiRs in human pancreatic islets and beta cells

    by Stefano Auddino, Elena Aiello, Giuseppina E. Grieco, Daniela Fignani, Giada Licata, Marco Bruttini, Alessia Mori, Andrea F. Berteramo, Erika Pedace, Laura Nigi, et al.

    Aims/hypothesis: MiRNAs regulate gene expression, influencing beta cell function and pathways. Isoforms of miRNA (isomiRs), sequence variants of miRNAs with post-transcriptional modifications, exhibit cell-type-specific expression and functions. Despite their biological significance, a comprehensive isomiR profile in human pancreatic islets and beta cells remains unexplored. This study aims to profile isomiR expression in four beta cell sources: (1) laser capture microdissected human islets (LCM-HI); (2) collagenase-isolated human islets (CI-HI); (3) sorted beta cells; and (4) the EndoC-βH1 beta cell line, and to investigate their potential role in beta cell function. Methods: Small RNA-seq and/or small RNA dataset analysis was conducted on human pancreatic islets and beta cells. Data were processed using the sRNAbench bioinformatics pipeline to classify isomiRs based on sequence variations. A beta cell-specific isomiR signature was identified via cross-validation across datasets. Correlations between LCM-HI isomiR expression and in vivo clinical parameters were analysed using regression models. Functional validation of isomiR-411-5p-Ext5p(+1) was performed via overexpression in EndoC-βH1 cells and CI-HI, followed by glucose-stimulated insulin secretion (GSIS) assays and/or transcriptomic analysis. Results: IsomiRs constituted 59.2 ± 1.9% (LCM-HI), 59.6 ± 2.4% (CI-HI), 42.3 ± 7.2% (sorted beta cells) and 43.8 ± 1.2% (EndoC-βH1) of total miRNA reads (data represented as mean ± SD), with 3′ end trimming (Trim3p) being the predominant modification. A beta cell-specific isomiR signature of 30 sequences was identified, with isomiR-411-5p-Ext5p(+1) showing a significant inverse correlation with basal insulin secretion (p=0.0009, partial R 2=0.68) and total insulin secretion (p=0.005, partial R 2=0.54). Overexpression of isomiR-411-5p-Ext5p(+1), but not of its canonical counterpart, importantly reduced GSIS by 51% ( ± 15.2%; mean ± SD) (p=0.01) in EndoC-βH1 cells. Transcriptomic analysis performed in EndoC-βH1 cells and CI-HI identified 47 genes significantly downregulated by isomiR-411-5p-Ext5p(+1) (false discovery rate [FDR]p=1.1 × 10⁻⁹). Conclusions/interpretation: This study provides the first comprehensive isomiR profiling in human islets and beta cells, revealing their substantial contribution to miRNA regulation. IsomiR-411-5p-Ext5p(+1) emerges as a distinct key modulator of insulin secretion and granule dynamics in beta cells. These findings highlight isomiRs as potential biomarkers and therapeutic targets for diabetes, warranting further exploration of their roles in beta cell biology. Graphical


  • Open Access

    Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?

    by C. Formichi, W. Baronti, G. de Gennaro, M. Cerrai Ceroni, L. Nigi, L. Rizzo, F. Dotta

    Purpose: To evaluate the variables influencing the therapeutic choice toward oral versus subcutaneous semaglutide in a cohort of diabetic subjects. Methods: We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022. Results: Oral semaglutide was preferentially prescribed in older subjects with longer disease duration in replacement of other antidiabetic drugs, while subcutaneous semaglutide was preferentially prescribed in add-on to metformin in subjects with higher body weight and BMI. After 6 months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction. No differences were found in terms of adverse events. Conclusion: In our experience, injectable semaglutide is preferred in patients with excess weight and shorter disease duration, while the oral formulation was used later and especially after therapeutic failure of previous therapies. Follow-up data indicate similar tolerability and efficacy of both formulations, despite subcutaneous semaglutide demonstrated greater efficacy.


  • Top Cited Papers
    Open Access

    New Advances in Metabolic Syndrome, from Prevention to Treatment: The Role of Diet and Food

    by Donatella Ambroselli, Fabrizio Masciulli, Enrico Romano, Giuseppina Catanzaro, Zein Mersini Besharat, Maria Chiara Massari, Elisabetta Ferretti, Silvia Migliaccio, Luana Izzo, Alberto Ritieni, et al.

    The definition of metabolic syndrome (MetS) has undergone several changes over the years due to the difficulty in establishing universal criteria for it. Underlying the disorders related to MetS is almost invariably a pro-inflammatory state related to altered glucose metabolism, which could lead to elevated cardiovascular risk. Indeed, the complications closely related to MetS are cardiovascular diseases (CVDs) and type 2 diabetes (T2D). It has been observed that the predisposition to metabolic syndrome is modulated by complex interactions between human microbiota, genetic factors, and diet. This review provides a summary of the last decade of literature related to three principal aspects of MetS: (i) the syndrome’s definition and classification, pathophysiology, and treatment approaches; (ii) prediction and diagnosis underlying the biomarkers identified by means of advanced methodologies (NMR, LC/GC-MS, and LC, LC-MS); and (iii) the role of foods and food components in prevention and/or treatment of MetS, demonstrating a possible role of specific foods intake in the development of MetS.


  • Open Access

    Intra-islet insulin synthesis defects are associated with endoplasmic reticulum stress and loss of beta cell identity in human diabetes

    by Noemi Brusco, Guido Sebastiani, Gianfranco Di Giuseppe, Giada Licata, Giuseppina E. Grieco, Daniela Fignani, Laura Nigi, Caterina Formichi, Elena Aiello, Stefano Auddino, et al.

    Aims/hypothesis: Endoplasmic reticulum (ER) stress and beta cell dedifferentiation both play leading roles in impaired insulin secretion in overt type 2 diabetes. Whether and how these factors are related in the natural history of the disease remains, however, unclear. Methods: In this study, we analysed pancreas biopsies from a cohort of metabolically characterised living donors to identify defects in in situ insulin synthesis and intra-islet expression of ER stress and beta cell phenotype markers. Results: We provide evidence that in situ altered insulin processing is closely connected to in vivo worsening of beta cell function. Further, activation of ER stress genes reflects the alteration of insulin processing in situ. Using a combination of 17 different markers, we characterised individual pancreatic islets from normal glucose tolerant, impaired glucose tolerant and type 2 diabetic participants and reconstructed disease progression. Conclusions/interpretation: Our study suggests that increased beta cell workload is accompanied by a progressive increase in ER stress with defects in insulin synthesis and loss of beta cell identity. Graphical


  • Open Access

    Follow-up after bariatric surgery: is it time to tailor it? Analysis of early predictive factors of 3-year weight loss predictors of unsuccess in bariatric patients

    by Costantino Voglino, Simona Badalucco, Andrea Tirone, Cristina Ciuoli, Silvia Cantara, Nicoletta Benenati, Annalisa Bufano, Caterina Formichi, Federica Croce, Ilaria Gaggelli, et al.

    Bariatric surgery (BS) is the most effective treatment strategy for obesity. Nevertheless, a subset of patients does not reach a successful weight loss or experience long-term weight regain. Conflicting evidence exists regarding predictors of BS outcomes. We aimed to define the early factors linked to 3 year unsuccessful weight loss in order to promote a tailored close follow-up. We enrolled 443 patients who underwent BS from January 2014 to December 2018 with a 3 year follow-up. An unsuccessful BS outcome was defined as a percentage of total weight loss (%TWL) < 20. We compared the characteristics between successful and unsuccessful patients in order to identify predictor factors of unsuccess after surgery. We found that the proportion of patients with unsuccessful weight loss progressively increased from one to three years after BS. In a multiple regression model, only 1 month %TWL and sleeve gastrectomy (SG) were significantly associated with 3 year unsuccessful weight loss. We stratified our cohort in four groups according to the risk of BS unsuccess, in terms of 1 month %TWL and type of surgery (SG vs gastric bypass). Interestingly, groups showed a significant difference in terms of %TWL at each follow-up point. Patients submitted to SG with lower 1 month %TWL must be considered at higher risk of future weight regain; consequently, they require a tailored and closer follow-up.Graphical abstract


  • Open Access

    Protocol to analyze circulating small non-coding RNAs by high-throughput RNA sequencing from human plasma samples

    by Giuseppina E. Grieco, Guido Sebastiani, Daniela Fignani, Noemi Brusco, Laura Nigi, Caterina Formichi, Giada Licata, Marco Bruttini, Romina D’aUrizio, Chantal Mathieu, et al.